This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hapangama, D. K. Articles by Baird, D. T. Search for Related Content PubMed PubMed Citation Articles by Hapangama, D. K. Articles by Baird, D. T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PROGESTERONE RU-486 Medline Plus Health Information Vaginal Bleeding

Mifepristone-Induced Vaginal Bleeding Is Associated with Increased Immunostaining for Cyclooxygenase-2 and Decrease in Prostaglandin Dehydrogenase in Luteal Phase Endometrium

Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, Edinburgh EH3 9ET, United Kingdom

Address all correspondence and requests for reprints to: Professor D. T. Baird, Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, 37 Chalmers Street, Edinburgh EH3 9ET, United Kingdom. E-mail: cdn{at}ed.ac.uk.

Abstract

The mechanism of mifepristone-induced vaginal bleeding and endometrial shedding was investigated in 13 women who took 200 mg mifepristone in the midluteal phase on d 8 after the onset of the urinary LH surge (LH+8). Endometrial biopsies were collected, 6–24 h after mifepristone (group 1, n = 7) or 36–48 h after mifepristone (group 2, n = 6), and compared with those from a control group in the midluteal phase (n = 7). All women reported vaginal bleeding commencing 36–48 h after taking mifepristone. Treatment with mifepristone significantly reduced serum progesterone levels in all women, when compared with the controls (13.2 nM vs. 34.8 nM, P = 0.001). After mifepristone, a significant increase in cyclooxygenase-2 immunoreactivity was apparent at 36–48 h (P = 0.0018), whereas prostaglandin 15 dehydrogenase enzyme-positive immunostaining declined, to be virtually absent by 36–48 h in both glands and in stroma (P < 0.05). There was no change in intensity or distribution of staining for steroid receptors after mifepristone. The changes in immunostaining for cyclooxygenase-2 and prostaglandin 15 dehydrogenase strongly support the hypothesis that an increase in the local concentration of prostaglandins in the endometrium is involved in the mechanism of bleeding induced by mifepristone in the luteal phase.

This article has been cited by other articles:

				D.K. Hapangama, M.A. Turner, J.A. Drury, S. Quenby, A. Hart, M. Maddick, C. Martin-Ruiz, and T. von Zglinicki Sustained replication in endometrium of women with endometriosis occurs without evoking a DNA damage response Hum. Reprod., March 1, 2009; 24(3): 687 - 696. [Abstract] [Full Text] [PDF]

				H. O. D. Critchley and P. T. K. Saunders Hormone Receptor Dynamics in a Receptive Human Endometrium Reproductive Sciences, February 1, 2009; 16(2): 191 - 199. [Abstract] [PDF]

				D.K. Hapangama, M.A. Turner, J.A. Drury, S. Quenby, G. Saretzki, C. Martin-Ruiz, and T. Von Zglinicki Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length Hum. Reprod., July 1, 2008; 23(7): 1511 - 1519. [Abstract] [Full Text] [PDF]

				R.D. Catalano, H.O. Critchley, O. Heikinheimo, D.T. Baird, D. Hapangama, J.R.A. Sherwin, D.S. Charnock-Jones, S.K. Smith, and A.M. Sharkey Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium Mol. Hum. Reprod., September 1, 2007; 13(9): 641 - 654. [Abstract] [Full Text] [PDF]

				N. Narvekar, H. O.D. Critchley, L. Cheng, and D. T. Baird Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor Hum. Reprod., September 1, 2006; 21(9): 2312 - 2318. [Abstract] [Full Text] [PDF]

				M. Vaisanen-Tommiska, R. Butzow, O. Ylikorkala, and T. S. Mikkola Mifepristone-induced nitric oxide release and expression of nitric oxide synthases in the human cervix during early pregnancy Hum. Reprod., August 1, 2006; 21(8): 2180 - 2184. [Abstract] [Full Text] [PDF]

				M. Parent, E. Madore, L. A MacLaren, and M. A Fortier 15-Hydroxyprostaglandin dehydrogenase in the bovine endometrium during the oestrous cycle and early pregnancy. Reproduction, March 1, 2006; 131(3): 573 - 582. [Abstract] [Full Text] [PDF]

				K. L. Terry, I. De Vivo, L. Titus-Ernstoff, P. M. Sluss, and D. W. Cramer Genetic Variation in the Progesterone Receptor Gene and Ovarian Cancer Risk Am. J. Epidemiol., March 1, 2005; 161(5): 442 - 451. [Abstract] [Full Text] [PDF]